Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas.
Peripheral T- and NK-cell lymphomas (PT/NKCLs) are relatively rare, and few studies have validated the International Prognostic Index (IPI) for PT/NKCLs in prospective clinical trials. Histopathological specimens from 136 patients, enrolled in six prospective multicenter trials of doxorubicin-containing regimens, with PT/NKCLs were reviewed by six hematopathologists following the WHO classification. This combined analysis demonstrated that the IPI was not predictive of prognosis for patients with PT/NKCLs as previously shown by GELA. In a univariate analysis, low total serum protein (TP) and albumin levels, gastrointestinal tract involvement, and histologic subtype (extranodal NK/T-cell lymphoma, nasal type, and peripheral T-cell lymphoma, unspecified) were significantly associated with reduced survival. In a multivariate analysis, TP (p = 0.004) and histologic subtype (p = 0.024) remained significant. We discuss the need to establish the importance and meaning of TP and to develop new strategies for patients with PT/NKCLs allowing for TP, especially with worse histologic subtypes.
Watanabe
Takashi
T
Hematology Division, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. takawata@ncc.go.jp
Kinoshita
Tomohiro
T
Itoh
Kuniaki
K
Yoshimura
Kenichi
K
Ogura
Michinori
M
Kagami
Yoshitoyo
Y
Yamaguchi
Motoko
M
Kurosawa
Mitsutoshi
M
Tsukasaki
Kunihiro
K
Kasai
Masaharu
M
Tobinai
Kensei
K
Kaba
Harumi
H
Mukai
Kiyoshi
K
Nakamura
Shigeo
S
Ohshima
Koichi
K
Hotta
Tomomitsu
T
Shimoyama
Masanori
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D001798:Blood Proteins / Q000378:metabolism*; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects / Q000473:pathology; D054391:Lymphoma, Extranodal NK-T-Cell / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D016411:Lymphoma, T-Cell, Peripheral / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D001798:Blood Proteins